Momentum from promising CLN-978 autoimmune data fuels 15.1% CGEM surge
Cullinan Therapeutics, Inc. operates as a biopharmaceutical firm actively advancing its therapeutic candidates through clinical trials. This company is focused on developing innovative treatments primarily for cancer, including those that leverage the immune system (immuno-oncology). Its current roster of investigational drugs comprises CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. Patrick A. Baeuerle founded the organization on September 15, 2016, and it is presently headquartered in Cambridge, Massachusetts.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | $18.94M | N/A | N/A | N/A |
| Cost of Revenue | $306.00K | N/A | N/A | N/A | $62.00K | $70.00K | $43.00K |
| Gross Profit | $-306.00K | N/A | N/A | $18.94M | $-62.00K | $-70.00K | $-43.00K |
| Gross Margin | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| Operating Expenses | $196.61M | $191.09M | $-144.65M | $86.90M | $60.27M | $22.20M | $14.54M |
| Operating Income | $-196.92M | $-191.09M | $144.65M | $-67.95M | $-60.34M | $-22.27M | $-14.59M |
| Operating Margin | 0.00% | 0.00% | 0.00% | -358.73% | 0.00% | 0.00% | 0.00% |
| Net Income | $-167.38M | $-153.16M | $111.21M | $-65.57M | $-51.80M | $-20.04M | $-14.19M |
| Net Margin | 0.00% | 0.00% | 0.00% | -346.14% | 0.00% | 0.00% | 0.00% |
| EPS (Basic) | $-3.11 | $-3.69 | $2.46 | $-1.48 | $-1.19 | $-19.70 | $-17.74 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A |